Anika Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Anika Therapeutics, Inc. (ANIK) had Available-for-sale Securities, Amortized Cost Basis of $22.01 million as of 2015-09-30, per its 10-Q filed 2015-11-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2015-11-03
- 2015-09-30: Available-for-sale Securities, Amortized Cost Basis $22.01M.
- 2015-06-30: Available-for-sale Securities, Amortized Cost Basis $18.52M.
- 2014-09-30: Available-for-sale Securities, Amortized Cost Basis $20.00M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2015-09-30 | $22.01M 10-Q · filed 2015-11-03 |
| 2015-06-30 | $18.52M 10-Q · filed 2015-08-04 |
| 2014-09-30 | $20.00M 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |